$229 Million is the total value of Prosight Management, LP's 38 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMY | New | BRISTOL MYERS SQUIBB CO | $13,502,000 | – | 283,000 | +100.0% | 5.91% | – |
| NVRO | New | NEVRO CORP | $8,049,000 | – | 128,765 | +100.0% | 3.52% | – |
| URGN | New | UROGEN PHARMA LTD | $5,831,000 | – | 157,862 | +100.0% | 2.55% | – |
| New | EXACT SCIENCES CORPput | $4,721,000 | – | 54,500 | +100.0% | 2.07% | – | |
| WAGE | New | WAGEWORKS INC | $4,377,000 | – | 115,926 | +100.0% | 1.92% | – |
| New | NEVRO CORPcall | $4,375,000 | – | 70,000 | +100.0% | 1.91% | – | |
| ACIU | New | AC IMMUNE SA | $3,588,000 | – | 710,541 | +100.0% | 1.57% | – |
| MTEM | New | MOLECULAR TEMPLATES INC | $1,730,000 | – | 297,790 | +100.0% | 0.76% | – |
| MGTX | New | MEIRAGTX HOLDINGS PLC | $1,573,000 | – | 91,317 | +100.0% | 0.69% | – |
| New | ALDEYRA THERAPEUTICS INCcall | $1,466,000 | – | 162,300 | +100.0% | 0.64% | – | |
| UROV | New | UROVANT SCIENCES LTD | $1,004,000 | – | 99,870 | +100.0% | 0.44% | – |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $68,000 | – | 709 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.